Surprisingly, ferrichrome drastically increased responsiveness of anti-PD-L1 antibody therapy in pancreatic tumors, suggesting that pancreatic cancer patients expressing PDL-1 may be more responsive to immune checkpoint blockade (ICB) therapies in the presence of ferrichrome. This evidence concerns the gene CD274 and familial pancreatic carcinoma.